Product Information
Registration Status: ActiveSIN05255P
FENFEDRIN CAPSULE is approved to be sold in Singapore with effective from 1990-12-14. It is marketed by APEX PHARMA MARKETING PTE LTD, with the registration number of SIN05255P.
This product contains Chlorpheniramine 4mg, and Pseudoephedrine 60mg in the form of CAPSULE. It is approved for ORAL use.
This product is manufactured by XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD in MALAYSIA.
It is a Pharmacy Only Medicine that can be obtained from a pharmacist at a retail pharmacy.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. [PubChem]
Indication
For the treatment of rhinitis, urticaria, allergy, common cold, asthma and hay fever.
Mechanism of Action
Chlorpheniramine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
Pharmacokinetics
- Absorption
- Well absorbed in the gastrointestinal tract.
- Distribution
- Metabolism
- Primarily hepatic via Cytochrome P450 (CYP450) enzymes.
- Elimination
Toxicity
Oral LD50 (rat): 306 mg/kg; Oral LD50 (mice): 130 mg/kg; Oral LD50 (guinea pig): 198 mg/kg [Registry of Toxic Effects of Chemical Substances. Ed. D. Sweet, US Dept. of Health & Human Services: Cincinatti, 2010.] Also a mild reproductive toxin to women of childbearing age.
Active Ingredient/Synonyms
1-(p-chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane | 1-(p-chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine | 2-[p-chloro-α-[2-(dimethylamino)ethyl]benzyl]pyridine | 3-(p-chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine | Chlorophenylpyridamine | Chlorphenamin | Chlorphenaminum | Chlorpheniramine | Chlorpheniramine polistirex | Chlorpheniraminum | Clorfenamina | Clorfeniramina | γ-(4-chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine | γ-(4-chlorophenyl)-γ-(2-pyridyl)propyldimethylamine | Chlorphenamine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Description
An alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used in the treatment of several disorders including asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.
Indication
For the treatment of nasal congestion, sinus congestion, Eustachian tube congestion, and vasomotor rhinitis, and as an adjunct to other agents in the optimum treatment of allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis. Also used as first-line therapy of priapism.
Mechanism of Action
Pseudoephedrine acts directly on both alpha- and, to a lesser degree, beta-adrenergic receptors. Through direct action on alpha-adrenergic receptors in the mucosa of the respiratory tract, pseudoephedrine produces vasoconstriction. Pseudoephedrine relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors. Like ephedrine, pseudoephedrine releasing norepinephrine from its storage sites, an indirect effect. This is its main and direct mechanism of action. The displaced noradrenaline is released into the neuronal synapse where it is free to activate the postsynaptic adrenergic receptors.
Pharmacokinetics
- Absorption
- Pseudoephedrine is readily and almost completely absorbed from the GI tract and there is no evidence of first-pass metabolism.
- Distribution
- Metabolism
- Hepatic.
- Elimination
Toxicity
Common adverse reactions include nervousness, restlessness, and insomnia. Rare adverse reactions include difficult/painful urination, dizziness/lightheadedness, heart palpitations, headache, increased sweating, nausea/vomiting, trembling, troubled breathing, unusual paleness, and weakness.
Active Ingredient/Synonyms
(+) threo-2-(methylamino)-1-phenyl-1-propanol | (+)-(1S,2S)-Pseudoephedrine | (+)-Pseudoephedrine | (+)-psi-Ephedrine | (+)-threo-Ephedrine | d-Isoephedrine | d-Pseudoephedrine | d-psi-2-Methylamino-1-phenyl-1-propanol | d-psi-Ephedrine | Isoephedrine | L-(+)-Pseudoephedrine | L(+)-psi-Ephedrine | Pseudoefedrina | pseudoéphédrine | Pseudoephedrine D-form | Pseudoephedrinum | Psi-ephedrin | Psi-ephedrine | trans-Ephedrine | ψ-ephedrine | Pseudoephedrine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.